<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40000760</article-id><article-id pub-id-type="pmc">PMC11862204</article-id>
<article-id pub-id-type="publisher-id">91400</article-id><article-id pub-id-type="doi">10.1038/s41598-025-91400-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Cardiac effects of two hallucinogenic natural products, <italic>N</italic>,<italic>N</italic>-dimethyl-tryptamine and 5-methoxy-<italic>N</italic>,<italic>N</italic>-dimethyl-tryptamine</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Neumann</surname><given-names>Joachim</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dietrich</surname><given-names>Tobias</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Azatsian</surname><given-names>Karyna</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hofmann</surname><given-names>Britt</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Gergs</surname><given-names>Ulrich</given-names></name><address><email>ulrich.gergs@medizin.uni-halle.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05gqaka33</institution-id><institution-id institution-id-type="GRID">grid.9018.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0679 2801</institution-id><institution>Institut f&#x000fc;r Pharmakologie und Toxikologie, Medizinische Fakult&#x000e4;t, </institution><institution>Martin-Luther-Universit&#x000e4;t Halle-Wittenberg, </institution></institution-wrap>Magdeburger Str. 4, 06097 Halle, Germany </aff><aff id="Aff2"><label>2</label>Department of Pharmacology and Toxicology, Faculty of Pharmacy, Gdansk, Poland </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04fe46645</institution-id><institution-id institution-id-type="GRID">grid.461820.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0390 1701</institution-id><institution>Department of Cardiac Surgery, Mid-German Heart Center, </institution><institution>University Hospital Halle, </institution></institution-wrap>06097 Halle, Germany </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><elocation-id>6715</elocation-id><history><date date-type="received"><day>16</day><month>4</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">It is unclear whether hallucinogenic tryptamine derivatives namely <italic>N</italic>,<italic>N</italic>-dimethyl-tryptamine (DMT) and 5-methoxy-<italic>N</italic>,<italic>N</italic>-dimethyl-tryptamine (5-MeO-DMT) exert positive inotropic effects in the human heart. Therefore, we measured the inotropic effects of these drugs in isolated left and right atrial preparations of mice that overexpress human 5-HT<sub>4</sub> receptors (5-HT<sub>4</sub>-TG) and preparations from wild type mice (WT). Moreover, we measured force of contraction in isolated right atrial preparations from adult patients, obtained in the process of open heart surgery due to severe coronary heart disease. DMT and 5-MeO-DMT augmented the force of contraction in isolated paced (1&#x000a0;Hz) left atrial preparations from 5-HT<sub>4</sub>-TG and raised the spontaneous beating rate of right atrial preparations from 5-HT<sub>4</sub>-TG. The drugs elevated force of contraction in paced (1&#x000a0;Hz) human right atrial muscle preparations. The maximum inotropic effects of DMT and 5-MeO-DMT were smaller at 10&#x000a0;&#x000b5;M (about 65%) than that of 1&#x000a0;&#x000b5;M 5-HT on the left atria from 5-HT<sub>4</sub>-TG. The maximum increase in the beating rate due to DMT and 5-MeO-DMT amounted 40&#x02009;&#x000b1;&#x02009;5% of the effect of 5-HT on right atrial preparations from 5-HT<sub>4</sub>-TG (<italic>n</italic>&#x02009;=&#x02009;5&#x02013;6). DMT and 5-MeO-DMT were inactive in WT. The potency of 5-MeO-DMT to increase force of contraction could be increased by pre-treatment of human atrial preparations by the phosphodiesterase inhibitor cilostamide (1&#x000a0;&#x000b5;M). 5-MeO-DMT increased the phosphorylation state of phospholamban at serine 16 in isolated left atrial muscle strips of 5-HT<sub>4</sub>-TG. In summary, DMT and 5-MeO-DMT acted as partial agonists on human 5-HT<sub>4</sub> receptors.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-91400-6.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Serotonin</kwd><kwd><italic>N</italic>,<italic>N</italic>-dimethyl-tryptamine (DMT)</kwd><kwd>5-Methoxy-<italic>N</italic>,<italic>N</italic>-dimethyl-tryptamine (5-MeO-DMT)</kwd><kwd>5-HT<sub>4</sub> receptor</kwd><kwd>Inotropy</kwd><kwd>Chronotropy</kwd><kwd>Transgenic mice</kwd><kwd>Human atrium</kwd><kwd>Phospholamban</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Drug safety</kwd><kwd>Receptor pharmacology</kwd><kwd>Adverse effects</kwd><kwd>Depression</kwd></kwd-group><funding-group><award-group><funding-source><institution>Martin-Luther-Universit&#x000e4;t Halle-Wittenberg (1043)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">The natural occurring molecules 5-methoxy-<italic>N</italic>,<italic>N</italic>-dimethyl-tryptamine (5-MeO-DMT) and <italic>N</italic>,<italic>N</italic>-dimethyl-tryptamine (DMT) are hallucinogenic drugs. They occur in South America mainly in plants of the Amazonas region<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. Perorally given alone, 5-MeO-DMT is inactivated rapidly by a first pass effect<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Hence, 5-MeO-DMT has to be injected or has to be supplemented with inhibitors of the enzymatic degradation<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. These enzyme inhibitors could be antidepressant drugs like tranylcypromine. There are also reports in the literature that pure 5-MeO-DMT was mixed with plants extracts harmine or harmaline to inhibit the first pass effect<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. DMT and 5-MeO-DMT are chemically similar to serotonin (5-HT; 5-hydroxy-tryptamine) and therefore can bind to several seven known classes of serotonin receptors. Stimulation of brain 5-HT<sub>2A</sub>-receptors explains the hallucinogenic effects of DMT and 5-MeO-DMT<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. DMT but not 5-MeO-DMT increased the beating rate in isolated rabbit hearts<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. However, serotonin acts in rabbit hearts by release of noradrenaline and not via serotonin receptors and hence rabbit hearts are not a good model for the human heart<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. In contrast to rabbits, in rats, 5-MeO-DMT decreased the heart rate<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. These effects were suggested to be due to stimulation of 5-HT<sub>1</sub> serotonin receptors<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. We had reported, in contrast, that 5-HT increased force of contraction in isolated atrial preparations from rats via 5-HT<sub>2A</sub> serotonin receptors<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. However, as far as we know, inotropic effects of DMT and 5-MeO-DMT have not yet been reported via 5-HT<sub>4</sub> receptors from any species. We have chosen to study these tryptamine derivatives because they are naturally occurring hallucinogenic drugs, forbidden to use in many countries, but popular for &#x0201c;recreational&#x0201d; purposes and sometimes leading to fatal intoxications. Thus, from a clinical perspective it would be helpful to know whether or not these drugs act as agonists at cardiac 5-HT<sub>4</sub> receptors, because then 5-HT<sub>4</sub> receptor antagonists could be used to treat the cardiac side effects of these intoxications. Hence, we tested the hypothesis that DMT and 5-MeO-DMT act as agonists on cardiac human 5-HT<sub>4</sub> serotonin receptors (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Parts of the data have been reported in abstract form<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>.</p><p id="Par3">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Structural formulas and proposed mechanism of action of DMT and 5-MeO-DMT. Ca<sup>2+</sup> passes the cardiac myocyte membrane via the L-type Ca<sup>2+</sup> channel (LTCC). This process can be enhanced by serotonin (5-HT), DMT and 5-MeO-DMT via activation of the 5-HT<sub>4</sub> receptor (inhibitable for example by tropisetron or GR125487). Agonists binding elevate the activity of the adenylyl cyclase (AC) in the sarcolemma via stimulatory G-proteins (G<sub>s</sub>). This elevates the cytosolic cAMP followed by activation of the cAMP-dependent protein kinase (PKA). PKA increases the phosphorylation state (P) of many proteins including LTCC, phospholamban (PLB) and the inhibitory subunit of troponin (TnI). These phosphorylation events lead to increased cardiac force generation and relaxation. When Ca<sup>2+</sup> passes through the LTCC, it can get into the vicinity of the ryanodine receptors (RYR). This leads finally to opening of the RYR and more Ca<sup>2+</sup> flows into the cytosol of the cardiomyocyte. When this released Ca<sup>2+</sup> binds to myofilaments, they contract more vigorously and this leads to an increase in force of contraction. In diastole, Ca<sup>2+</sup> is pumped into the sarcoplasmic reticulum via a sarcoplasmic reticulum Ca<sup>2+</sup> ATPase (SERCA). The activity of SERCA is enhanced by an augmented phosphorylation state of PLB.</p></caption><graphic xlink:href="41598_2025_91400_Fig1_HTML" id="d33e371"/></fig>
</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Transgenic mice</title><p id="Par4">A mouse with cardiomyocyte-specific expression of the human 5-HT<sub>4a</sub> receptor has been generated in our laboratories<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. The cardiac myocyte-specific expression was achieved by the use of the &#x003b1;-myosin heavy chain promoter. The age of the animals studied in the atrial contraction experiments was around 154&#x000a0;days. All mice were housed under conditions of optimum light, temperature and humidity with food and water provided ad libitum. The investigation conformed to the Guide for the Care and Use of Laboratory Animals as published by the National Research Council (2011). The animals were handled and maintained according to the approved protocols of the Animal Welfare Committee of the University of Halle-Wittenberg, Halle, Germany. The study was conducted in accordance with ARRIVE guidelines<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>.</p></sec><sec id="Sec4"><title>Contractile studies on mouse atrial preparations</title><p id="Par5">In brief, mice were euthanized by intraperitoneal injection of sodium pentobarbital (250&#x000a0;mg/kg body weight)<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Then, the right and left atrial preparations were isolated and mounted in organ baths as previously described<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. The bathing solution of the organ baths contained 119.8&#x000a0;mM NaCI, 5.4&#x000a0;mM KCI, 1.8&#x000a0;mM CaCl<sub>2</sub>, 1.05&#x000a0;mM MgCl<sub>2</sub>, 0.42&#x000a0;mM NaH<sub>2</sub>PO<sub>4</sub>, 22.6&#x000a0;mM NaHCO<sub>3</sub>, 0.05&#x000a0;mM Na<sub>2</sub>EDTA, 0.28&#x000a0;mM ascorbic acid and 5.05&#x000a0;mM glucose. The solution was continuously gassed with 95% O<sub>2</sub> and 5% CO<sub>2</sub> and maintained at 37&#x000a0;&#x000b0;C and pH 7.4<sup><xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref></sup>. Spontaneously beating right atrial preparations from mice were used to study any chronotropic effects and the left atrial preparations were field stimulated with a frequency of 1&#x000a0;Hz to study force of contraction.</p><p id="Par6">The drug application was as follows. After equilibration was reached, 1&#x000a0;nM to 10&#x000a0;&#x000b5;M DMT or 5-MeO-DMT was added to the atrial preparations to establish concentration-response curves followed directly by a concentration-response curve of 5-HT (1&#x000a0;nM to 1&#x000a0;&#x000b5;M). This was to test if DMT or 5-MeO-DMT behave as full or partial agonists. After washout, again a concentration-response curve for DMT or 5-MeO-DMT (1&#x000a0;nM to 10&#x000a0;&#x000b5;M was performed to test if there are any desensitization effects that could compromise the results.</p></sec><sec id="Sec5"><title>Contractile studies on human atrial preparations</title><p id="Par7">The contractile studies on human preparations were done using the same setup and buffer as used in the mouse studies (see section above). The right atrial preparations were obtained from 14 male and two female patients aged 59&#x02013;78&#x000a0;years (mean&#x02009;&#x000b1;&#x02009;SD: 68.9&#x02009;&#x000b1;&#x02009;6.4&#x000a0;years) undergoing bypass surgery. Further details on patient characteristics are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Our methods used for atrial contraction studies in human samples have been previously published and were not altered in this study<sup><xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref></sup>. This study has been performed in accordance with the Declaration of Helsinki. The study protocol was approved by the local ethics committee of the Medical Faculty of the Martin Luther University Halle-Wittenberg (Ethics approval number: hm-b&#x000fc; 04.08.2005) and all research was performed in accordance with relevant guidelines/regulations. Informed consent was obtained from all patients included in the study.</p><p id="Par8">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Patient ID</th><th align="left">Sex</th><th align="left">Age (years)</th><th align="left">NYHA class</th><th align="left">CCS angina grading scale</th><th align="left">LVEF (%)</th><th align="left">Cardiac catheterization findings</th><th align="left">Medication</th></tr></thead><tbody><tr><td align="left">#1</td><td align="left">M</td><td align="left">78</td><td align="left">III</td><td align="left">IV</td><td align="left">65</td><td align="left">2 vessel CHD</td><td align="left">Acetylsalicylic acid, ramipril, metoprolol, torasemide, pantoprazole, alendronic acid, methylprednisolone, insulin</td></tr><tr><td align="left">#2</td><td align="left">F</td><td align="left">64</td><td align="left">III&#x02013;IV</td><td align="left">III&#x02013;IV</td><td align="left">35</td><td align="left">2 vessel CHD, AoS</td><td align="left">Acetylsalicylic acid, atorvastatin, telmisartan, hydrochlorothiazide, pantoprazole, anastrozole, metformin</td></tr><tr><td align="left">#3</td><td align="left">M</td><td align="left">74</td><td align="left">II</td><td align="left">III&#x02013;IV</td><td align="left">60</td><td align="left">2 vessel CHD, NSTEMI</td><td align="left">Metoprolol, apixaban, atorvastatin, torasemide</td></tr><tr><td align="left">#4</td><td align="left">M</td><td align="left">74</td><td align="left">III</td><td align="left">IV</td><td align="left">40</td><td align="left">2 vessel CHD</td><td align="left">Acetylsalicylic acid, bisoprolol, atorvastatin, ramipril, prasugrel, dapagliflozin, sitagliptin, pantoprazole, torasemide</td></tr><tr><td align="left">#5</td><td align="left">M</td><td align="left">74</td><td align="left">II</td><td align="left">III&#x02013;IV</td><td align="left">55</td><td align="left">3 vessel CHD, STEMI</td><td align="left">Acetylsalicylic acid, bisoprolol, atorvastatin, clopidogrel, torasemide, valsartan</td></tr><tr><td align="left">#6</td><td align="left">M</td><td align="left">59</td><td align="left">III</td><td align="left">III</td><td align="left">40</td><td align="left">3 vessel CHD, NSTEMI</td><td align="left">Acetylsalicylic acid, metoprolol, allopurinol, clopidogrel, pantoprazole, simvastatin, torasemide</td></tr><tr><td align="left">#7</td><td align="left">M</td><td align="left">77</td><td align="left">II</td><td align="left">III</td><td align="left">55</td><td align="left">3 vessel CHD, LMCA stenosis</td><td align="left">Clopidogrel, apixaban, nebivolol, calcium acetate, doxazosin, moxonidine, pantoprazole, sevelamer carbonate, torasemide, methylprednisolone, xipamide</td></tr><tr><td align="left">#8</td><td align="left">M</td><td align="left">61</td><td align="left">III</td><td align="left">III</td><td align="left">72</td><td align="left">3 vessel CHD, LMCA stenosis</td><td align="left">Acetylsalicylic acid, bisoprolol, allopurinol, atorvastatin, enalapril, hydrochlorothiazide, omega-3-acid ethyl esters, pantoprazole, budesonide, salbutamol</td></tr><tr><td align="left">#9</td><td align="left">M</td><td align="left">72</td><td align="left">III</td><td align="left">III&#x02013;IV</td><td align="left">55</td><td align="left">2 vessel CHD, NSTEMI</td><td align="left">Acetylsalicylic acid, torasemide, pantoprazole, tamsulosin, ezetimibe, candesartan, atorvastatin, amlodipine, apixaban</td></tr><tr><td align="left">#10</td><td align="left">M</td><td align="left">71</td><td align="left">II&#x02013;III</td><td align="left">III</td><td align="left">50</td><td align="left">3 vessel CHD, AoS</td><td align="left">Acetylsalicylic acid, metoprolol, amlodipine, atorvastatin, chlorthalidone, moxonidine, pantoprazole, torasemide, valsartan, insulin</td></tr><tr><td align="left">#11</td><td align="left">M</td><td align="left">60</td><td align="left">II</td><td align="left">III</td><td align="left">50</td><td align="left">3 vessel CHD, LMCA stenosis</td><td align="left">Acetylsalicylic acid, metoprolol, candesartan, dapagliflozin, sitagliptin, rosuvastatin, metformin, clopidogrel, terbinafine</td></tr><tr><td align="left">#12</td><td align="left">M</td><td align="left">59</td><td align="left">III</td><td align="left">III</td><td align="left">30</td><td align="left">3 vessel CHD, ICM</td><td align="left">Acetylsalicylic acid, metoprolol, atorvastatin, sacubitril/valsartan, ezetimibe, dapagliflozin, metformin, pantoprazole, spironolactone, torasemide</td></tr><tr><td align="left">#13</td><td align="left">F</td><td align="left">75</td><td align="left">III</td><td align="left">III&#x02013;IV</td><td align="left">40</td><td align="left">3 vessel CHD, NSTEMI, ICM</td><td align="left">Acetylsalicylic acid, metoprolol, atorvastatin, ezetimibe, ramipril, pantoprazole, prednisolone, torasemide, metamizole</td></tr><tr><td align="left">#14</td><td align="left">M</td><td align="left">71</td><td align="left">III</td><td align="left">III&#x02013;IV</td><td align="left">55</td><td align="left">3 vessel CHD, STEMI, AoS</td><td align="left">Acetylsalicylic acid, metoprolol, atorvastatin, candesartan, ezetimibe, pantoprazole, torasemide</td></tr><tr><td align="left">#15</td><td align="left">M</td><td align="left">68</td><td align="left">III&#x02013;IV</td><td align="left">III</td><td align="left">23</td><td align="left">3 vessel CHD, NSTEMI, AoS</td><td align="left">Acetylsalicylic acid, metoprolol, amlodipine, atorvastatin, sacubitril/valsartan, eplerenone, glimepiride, dapagliflozin, pantoprazole, metformin, budesonide/formoterol, torasemide, insulin</td></tr><tr><td align="left">#16</td><td align="left">M</td><td align="left">65</td><td align="left">III</td><td align="left">III</td><td align="left">40</td><td align="left">3 vessel CHD, LMCA stenosis, STEMI</td><td align="left">Acetylsalicylic acid, metoprolol, acetyl cysteine, atorvastatin, levothyroxine, pantoprazole, torasemide, metamizole, insulin</td></tr><tr><td align="left">Mean&#x02009;&#x000b1;&#x02009;SD</td><td align="left"/><td align="left">68.9&#x02009;&#x000b1;&#x02009;6.4</td><td align="left"/><td align="left"/><td align="left">47.8&#x02009;&#x000b1;&#x02009;12.7</td><td align="left"/><td align="left"/></tr></tbody></table><table-wrap-foot><p><italic>NYHA</italic> New York Heart Association, <italic>CCS</italic> Canadian Cardiovascular Society, <italic>LVEF</italic> left ventricular ejection fraction, <italic>CHD</italic> coronary heart disease, <italic>AoS</italic> aortic stenosis, <italic>STEMI</italic> ST-segment elevation myocardial infarction, <italic>NSTEMI</italic> non-ST-segment elevation myocardial infarction, <italic>LMCA</italic> left main coronary artery, <italic>ICM</italic> ischemic cardiomyopathy.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec6"><title>Western blotting</title><p id="Par9">The homogenization of the samples, protein measurements, electrophoresis, primary and secondary antibody incubation and quantification were performed following our previously established protocols<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref></sup>. Briefly, samples were homogenized in a buffer containing 10&#x000a0;mM NaHCO<sub>3</sub> and 5% SDS. Electrophoresis was performed in Novex&#x02122; 4&#x02013;20% &#x0201c;Tris&#x02013;Glycine Plus Midi Protein Gels&#x0201d; (Invitrogen, Thermo Fisher Scientific, Waltham, Massachusetts, USA). Subsequently, the proteins were transferred to a nitrocellulose membrane (Amersham Protran 0.45&#x000a0;&#x000b5;M, Cytiva, Germany) by wet transfer in a phosphate buffer (42&#x000a0;mM Na<sub>2</sub>HPO<sub>4</sub>, 8&#x000a0;mM NaH<sub>2</sub>PO<sub>4</sub>) for four Ampere hours at 4&#x000a0;&#x000b0;C. Following primary antibodies were used: anti serine 16-phosphorylated phospholamban (PS16-PLB; 1:5000; #A010-12AP; Badrilla, Leeds, UK), anti calsequestrin as a cardiac myocytes-specific loading control (CSQ; 1:20.000; #ab3516; abcam, Cambridge, UK). The signals were visualized by using chemiluminescence (Immobilon&#x02122; Western, Millipore, Merck; Darmstadt, Germany) and a digital imaging system (Amersham ImageQuant 800; Cytiva Europe GmbH, Freiburg im Breisgau, Germany).</p></sec><sec id="Sec7"><title>Data analysis</title><p id="Par10">Data shown are means &#x000b1; standard deviation. Recordings and primary analyses of contraction data were done with LabChart 8 (ADInstruments, Spechbach, Germany) and primary analyses of Western blots were performed with ImageQuant 10 (Cytiva, Freiburg, Germany). Statistical analyses and preparation of graphics were done with Prism 9.0 (GraphPad Software, San Diego, California, USA) using the analysis of variance followed by Bonferroni&#x02019;s posttest. A <italic>p</italic> value&#x02009;&#x0003c;&#x02009;0.05 was considered to be significant.</p></sec><sec id="Sec8"><title>Drugs and materials</title><p id="Par11">Serotonin (5-HT) hydrochloride was purchased from Sigma-Aldrich (Germany). Dimethyl-tryptamine (DMT) was purchased as solution (1&#x000a0;mg/ml in methanol) from Sigma-Aldrich (Germany) or as solid compound from LGC GmbH (Luckenwalde, Germany). 5-methoxy-dimethyl-tryptamine (5-MeO-DMT) was purchased as solid compound from Sigma-Aldrich (Germany) as well as from LGC GmbH (Luckenwalde, Germany). Both drugs were diluted/dissolved in a 50% DMSO and 50% water mixture and stored at &#x02212;&#x02009;20&#x000a0;&#x000b0;C. GR125487 was purchased from TOCRIS (Bio-Techne, Wiesbaden, Germany). All other chemicals were of the highest purity grade commercially available. Deionized water was used throughout the experiments. Stock solutions were prepared fresh daily.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Studies in the isolated left atria from mice</title><p id="Par12">We have previously shown that 5-HT increases the force of contraction in left atria from 5-HT<sub>4</sub>-TG, but not in left atria from WT<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Here, as a next step, we wanted to compare those data with those of DMT and 5-MeO-DMT, and we wanted to determine whether they also exert positive inotropic effects in 5-HT<sub>4</sub>-TG.</p><p id="Par13">Like serotonin also its derivative DMT (original recording: Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A) raised force in a concentration- and time-dependent manner in left atrial preparations from 5-HT<sub>4</sub>-TG. The data on force of contraction are summarized in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B and the time parameters of the contraction are summarized in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>D. Corresponding to the increase of the force at 10 &#x000b5;M DMT, the time of relaxation was shortened, indicative for a cAMP-dependent mechanism. Thereafter, we applied additionally in a cumulative way increasing concentrations of 5-HT (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A). DMT was less potent and less effective than 5-HT (pEC<sub>50</sub>&#x02009;=&#x02009;8.3) to raise force of contraction (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A,B). Previously, we had noted that 5-HT rapidly and effectively desensitized the 5-HT<sub>4</sub> receptor under our experimental conditions<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Hence, the question arose whether DMT would also lead to functional desensitization. Therefore, we washed out the effects of DMT and 5-HT (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A, washout), and subsequently, DMT was reapplied cumulatively. Once more, DMT elicited a positive inotropic effect (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A). These data are summarized in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B (second CRC). In parallel, by using the spontaneously beating right atria, we estimated whether under these conditions DMT affected the beating rate. As depicted in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C, DMT exerted a very small, negligible positive chronotropic effect. Like in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A, we then added cumulatively 5-HT. DMT was less potent and less effective to raise beating rate than 5-HT (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C). DMT, like 5-HT<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>, failed to affect the force of contraction or the beating rate in WT (data not shown).</p><p id="Par14">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Effects of DMT on mouse atrial preparations. (<bold>A</bold>) Original recording: Effect of DMT and serotonin on force of contraction in an isolated paced (1&#x000a0;Hz) left atrial preparation of a 5-HT<sub>4</sub> receptor overexpressing mouse (5-HT<sub>4</sub>-TG). At the end of the concentration response curve for DMT (CRC), serotonin (5-HT) was applied. Then washout was performed and again DMT was given (2nd CRC). Horizontal bar: time axis in minutes (min). Vertical bar: developed tension in milli Newton (mN). (<bold>B</bold>) Summarized effects of DMT and serotonin on force of contraction in isolated electrically driven (1&#x000a0;Hz) left atria of 5-HT<sub>4</sub>-TG mice. (<bold>C</bold>) Summarized effects of DMT and serotonin on the beating rate in isolated spontaneously beating right atria of 5-HT<sub>4</sub>-TG mice. (<bold>D</bold>) Summarized effects of DMT on time to peak tension (TTP) and time of relaxation (TR) in left atria of 5-HT<sub>4</sub>-TG mice. *First significant difference (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) versus control (Ctr, predrug value); <sup>#</sup>First significant difference (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) versus 10&#x000a0;&#x000b5;M DMT. Numbers in brackets indicate number of experiments.</p></caption><graphic xlink:href="41598_2025_91400_Fig2_HTML" id="d33e937"/></fig>
</p><p id="Par15">Next, we tested 5-MeO-DMT and found that 5-MeO-DMT raised force in a concentration- and time-dependent manner in left atrial preparations from 5-HT<sub>4</sub>-TG (original recording: Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A). The data on force of contraction are summarized in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B and the time parameters of the contraction are summarized in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>D. Compared to DMT, 5-MeO-DMT was more potent and effective to raise force of contraction and, accordingly, the shorting of time parameters was more pronounced (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>D). Thereafter, as done for DMT, we applied additionally in a cumulative way increasing concentrations of 5-HT (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A). 5-MeO-DMT (pEC<sub>50</sub>&#x02009;~&#x02009;5.8) seemed to be less potent but as effective as 5-HT to raise force of contraction (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A). In other words, additionally applied 5-HT could not raise force of contraction further (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A). However, given the experimental setup, it was not clearly possible to determine whether 5-MeO-DMT is a partial agonist in 5-HT<sub>4</sub>-TG, as the preparations had reached their maximal ability concerning contraction and beating rate. Therefore, the serotonin component was omitted from the graph of Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B. Finally, after washout, 5-MeO-DMT was applied again and 5-MeO-DMT induced again a positive inotropic effect (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A). These data are summarized in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B (second CRC). Here, also the right atria were used to study whether under these conditions 5-MeO-DMT affected the beating rate. As depicted in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>C and 5-MeO-DMT exerted a positive chronotropic effect. Like in left atria, we then added cumulatively 5-HT. 5-MeO-DMT seemed to be less potent but as effective as 5-HT to raise the beating rate, but for the reasons described above, the serotonin component was omitted from the graph of Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>C. 5-MeO-DMT, like 5-HT<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>, failed to affect the force of contraction or the beating rate in WT (data not shown).</p><p id="Par16">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Effects of 5-MeO-DMT on mouse atrial preparations. (<bold>A</bold>) Original recording: Effect of 5-MeO-DMT and serotonin on force of contraction in an isolated paced (1&#x000a0;Hz) left atrial preparation of a 5-HT<sub>4</sub> receptor overexpressing mouse (5-HT<sub>4</sub>-TG). At the end of the concentration response curve for 5-MeO-DMT (1st CRC), serotonin (5-HT) was applied. Then washout was performed and again 5-MeO-DMT was given (2nd CRC). Horizontal bar: time axis in minutes (min). Vertical bar: developed tension in milli Newton (mN). (<bold>B</bold>) Summarized effects of 5-MeO-DMT on force of contraction in isolated electrically driven (1&#x000a0;Hz) left atria of 5-HT<sub>4</sub>-TG mice. (<bold>C</bold>) Summarized effects of 5-MeO-DMT on the beating rate in isolated spontaneously beating right atria of 5-HT<sub>4</sub>-TG mice. (<bold>D</bold>) Summarized effects of 5-MeO-DMT on time to peak tension (TTP) and time of relaxation (TR) in left atria of 5-HT<sub>4</sub>-TG mice. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 versus control (Ctr, predrug value). Numbers in brackets indicate number of experiments.</p></caption><graphic xlink:href="41598_2025_91400_Fig3_HTML" id="d33e1024"/></fig>
</p><p id="Par17">Even though we could not calculate the EC<sub>50</sub> values for DMT and 5-MeO-DMT because the concentration-response curves did not reach a plateau in the concentration range achievable in this study, it is obvious that 5-HT is the most potent compound, followed by 5-MeO-DMT, while DMT has the lowest potency. This order is reflected in the kinetic parameters of the substances, as shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>. The time to reach the maximum force of contraction was shortest for 5-HT and slowest for DMT (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). In detail, 5-HT (t<sub>max50</sub> = 56&#x000a0;s) increased the force of contraction approximately twice as fast as 5-MeO-DMT (t<sub>max50</sub> = 130&#x000a0;s) and 5-MeO-DMT increased the force of contraction approximately twice as fast as DMT (t<sub>max50</sub> = 246&#x000a0;s) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).</p><p id="Par18">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Time-dependent increase of force of contraction in isolated electrically stimulated (1&#x000a0;Hz) left atria of 5-HT<sub>4</sub>-TG mice. (<bold>A</bold>) Time-dependent effect of 10 &#x000b5;M DMT, (<bold>B</bold>) of 3 &#x000b5;M 5-MeO-DMT, and (<bold>C</bold>) of 10 nM serotonin (5-HT). At the specified drug concentrations, the developed force of contraction was expressed as delta force normalized to the maximum effect. The time to reach the half maximum effect (t<sub>max</sub>&#x000bd;) is provided below the corresponding graph, along with the 95% confidence interval (CI). *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 versus control (Ctr, predrug value). Numbers in brackets indicate number of experiments.</p></caption><graphic xlink:href="41598_2025_91400_Fig4_HTML" id="d33e1072"/></fig>
</p><p id="Par19">As depicted in the scheme in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, we hypothesized that DMT and 5-MeO-DMT would increase the phosphorylation state of phospholamban at serine-16 (PS16-PLB). Hence, a separate set of contraction experiments was performed. We added 10&#x000a0;&#x000b5;M DMT or 5-MeO-DMT to left atrial preparations of 5-HT<sub>4</sub>-TG and WT until the maximum effect was reached (10&#x000a0;min) and then froze the atria. From these frozen atria, we performed and quantified Western blots. We noted that 5-MeO-DMT, but not DMT, increased the phosphorylation state of phospholamban in left atrial preparations from 5-HT<sub>4</sub>-TG but not WT (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). This is depicted in original Western blots (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>A) and summarized in bar diagrams (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>B,C). A stimulation of &#x003b2;-adrenoceptors by isoprenaline was used as positive control. Moreover, boiling of the sample shifted the phospholamban band from the pentameric form to the monomeric form: this effect was used to clearly identify the phospholamban band in the Western blot (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>A).</p><p id="Par20">
<fig id="Fig5"><label>Fig. 5</label><caption><p>Phosphorylation of phospholamban (PLB) in mouse atrial preparations. (<bold>A</bold>) Typical Western blots: Effect of 10 &#x000b5;M 5-MeO-DMT and DMT on PLB serine-16 phosphorylation (PS16-PLB) in isolated electrically stimulated left atrium (LA) from wild type (WT) and 5-HT<sub>4</sub> transgenic (5-HT<sub>4</sub>-TG) mice. Isoprenaline was used as positive control and boiling of the control sample shifted the PLB band from the pentameric form (p) to the monomeric form (m): this effect was used to identify the PLB band in the Western blot. Calsequestrin (CSQ) a constitutively expressed cardiac protein was used as loading control. For assessment of the expression of different proteins on one gel, the blots were cut and the lower and upper halves were incubated with different primary antibodies. (<bold>B</bold>) Summarized effects of DMT on the phosphorylation state of PLB in left atria (LA) and right atria (RA) of WT and 5-HT<sub>4</sub>-TG mice. (<bold>C</bold>) Summarized effects of 5-MeO-DMT on the phosphorylation state of PLB in LA and RA of WT and 5-HT<sub>4</sub>-TG mice. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 versus WT. Numbers in bars indicate number of experiments.</p></caption><graphic xlink:href="41598_2025_91400_Fig5_HTML" id="d33e1126"/></fig>
</p></sec><sec id="Sec11"><title>Studies in the isolated atria from humans</title><p id="Par21">Now, the question arose whether these functional effects are confined to transgenic mice or also have clinical relevance in humans. Hence, we studied human atrial preparations to measure force under electrically stimulated isometric conditions. In general, the contraction data from human preparations showed a larger scatter compared to mouse preparations, which is due to the heterogeneity regarding, e.g., age, genetic background, health status, disease and medication of the patients included in the study (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), which probably also applies to the serotonin receptor density. DMT alone did not increase force of contraction in isolated electrically paced right atrial muscle strips from patients (<italic>n</italic>&#x02009;=&#x02009;5), but in the presence of the phosphodiesterase III inhibitor cilostamide, a positive inotropic effect of 10&#x000a0;&#x000b5;M DMT was seen (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>A). This positive inotropic effect of DMT was antagonized by tropisetron (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>A) and by the 5-HT<sub>4</sub> receptor antagonist GR125487. The data are summarized in Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>A. Tropisetron itself did not affect the force of contraction as demonstrated by the control experiments shown in Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>E. The decline of force of contraction after 10&#x000a0;&#x000b5;M tropisetron was not different from the time-dependent decline of force of contraction (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>E). These control experiments were repeated three times, giving the same results.</p><p id="Par22">
<fig id="Fig6"><label>Fig. 6</label><caption><p>Effects of DMT and 5-MeO-DMT on isolated electrically driven (1&#x000a0;Hz) human right atrial preparations. (<bold>A</bold>) Effect of DMT on force of contraction in human right atrium. DMT alone was ineffective, but in the additional presence of cilostamide, a phosphodiesterase III inhibitor, a positive inotropic effect was seen that was antagonized by tropisetron. (<bold>B</bold>) Example of a patient where 5-MeO-DMT alone increased force of contraction and this increase was accompanied by an increased phosphorylation state at serine-16 of phospholamban (PS16-PLB) (<bold>C</bold>). Calsequestrin (CSQ) was used as loading control. (<bold>D</bold>) In other patients, 5-MeO-DMT increased force of contraction only in the presence of cilostamide and this positive inotropic effect of 5-MeO-DMT was antagonized by tropisetron. (<bold>E</bold>) Control experiments were performed with 10 &#x000b5;M tropisetron alone and in the absence of any compound (time control). (<bold>F</bold>) The positive inotropic effect of 5-MeO-DMT (in presence of cilostamide) was also antagonized by the specific 5-HT<sub>4</sub> receptor antagonist GR125487. Horizontal bar in original recordings: time axis in minutes (min). Vertical bar in original recordings: developed tension in milli Newton (mN).</p></caption><graphic xlink:href="41598_2025_91400_Fig6_HTML" id="d33e1186"/></fig>
</p><p id="Par23">
<fig id="Fig7"><label>Fig. 7</label><caption><p>Summarized effects of DMT, DMT&#x02009;+&#x02009;tropisetron (Trop) and DMT&#x02009;+&#x02009;GR125487 (GR) (<bold>A</bold>) and 5-MeO-DMT, 5-MeO-DMT&#x02009;+&#x02009;tropisetron and 5-MeO-DMT&#x02009;+&#x02009;GR125487 (<bold>B</bold>) on force of contraction in human right atrium normalized to cilostamide (Cilo). *Significant differences (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) between indicated groups. Numbers in bars indicate number of experiments. (<bold>C</bold>) concentration-response curves of DMT and 5-MeO-DMT in human right atrial preparations pre-stimulated with cilostamide (1 &#x000b5;M). *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 versus control (Ctr, pre-drug value); <sup>+</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 versus cilostamide. Numbers in brackets indicate number of experiments.</p></caption><graphic xlink:href="41598_2025_91400_Fig7_HTML" id="d33e1217"/></fig>
</p><p id="Par24">The effects of 5-MeO-DMT were different from those of DMT. In the atrial preparations from some patients (<italic>N</italic>&#x02009;=&#x02009;3) with an apparently high responsiveness to positive inotropic substances for unknown reasons, we noted that 5-MeO-DMT alone increased the force of contraction (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>B) and this increase was accompanied by an increased phospholamban phosphorylation (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>C). In the atrial preparations from other patients (<italic>N</italic>&#x02009;=&#x02009;9) with an apparently lower responsiveness to positive inotropic substances, 5-MeO-DMT increased the force of contraction, as observed for DMT, only in the presence of cilostamide (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>D). This positive inotropic effect of 10&#x000a0;&#x000b5;M 5-MeO-DMT was antagonized by tropisetron (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>D) as well as by the 5-HT<sub>4</sub> receptor antagonist GR125487 (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>F). The effect of 5-MeO-DMT was concentration-dependent und is summarized in Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>B. In a further series of experiments, in the presence of cilostamide, concentration-response curves for DMT and 5-MeO-DMT were performed from 0.1 to 100&#x000a0;&#x000b5;M (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>C). Here, the potency and efficacy of DMT and 5-MeO-DMT appeared to be the same. Unfortunately, the pEC<sub>50</sub> values could not be calculated accurately because the plateau of the concentration-response curves was not reached even at 100&#x000a0;&#x000b5;M, a concentration usually not reached in humans. An approximate estimate gave a pEC<sub>50</sub>&#x02009;&#x02264;&#x02009;4.5 for both DMT and 5-MeO-DMT in the human atrium. The evaluation of the time parameters revealed that the time to peak tension and the time of relaxation were shortened in a concentration-dependent manner by DMT and 5-MeO-DMT (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>A,C). The contraction kinetics of DMT and 5-MeO-DMT in the human atria (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>B,D) were similar to the kinetics found in the 5-HT<sub>4</sub>-TG atria (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). That is, 5-MeO-DMT reaches the maximum inotropic effect for a given concentration almost twice as fast as DMT.</p><p id="Par25">
<fig id="Fig8"><label>Fig. 8</label><caption><p>Effects of DMT (<bold>A</bold>) and 5-MeO-DMT (<bold>C</bold>) on time to peak tension (TTP) and time of relaxation (TR) in human right atrial preparations pre-stimulated with cilostamide (1 &#x000b5;M). (<bold>B</bold>) Time-dependent effect of 10 &#x000b5;M DMT and (<bold>D</bold>) of 10 &#x000b5;M 5-MeO-DMT. At the specified drug concentrations, the developed force of contraction was expressed as delta force normalized to the maximum effect. The time to reach the half maximum effect (t<sub>max</sub>&#x000bd;) is provided below the corresponding graph, along with the 95% confidence interval (CI). *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 versus control (Ctr, predrug value); <sup>+</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 versus cilostamide. Numbers in brackets indicate number of experiments.</p></caption><graphic xlink:href="41598_2025_91400_Fig8_HTML" id="d33e1299"/></fig>
</p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par26">The new finding of this study is the observation that DMT, and particularly 5-MeO-DMT, increases cardiac contractility via human 5-HT<sub>4</sub> receptors in the heart.</p><p id="Par27">DMT occurs in plants<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> and one has used DMT in religious settings<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup>. DMT can be found, for instance, in leaves of <italic>Diplopterys cabreana</italic> in Colombia and Ecuador<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>. There are drug preparations in Brazil (Amazonas region) that are called ayahuasca: they include parts from the plant <italic>Banisteriopsis caapi</italic>. DMT is degraded by the enzyme monoamine oxidase A (MAO-A) that physiologically occurs in the gastrointestinal tract: therefore users added plant extracts that contain MAO-A inhibitors, which also inhibit MAO-B at higher concentrations<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup>. Moreover, DMT is present in about 50 plants in South America<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. The so called ayahuasca (a Quechua word translated as &#x0201c;vine of the souls&#x0201d;<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>) is a mixture of at least DMT and endogenous MAO inhibitors<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. In more detail, ayahuasca is said to be prepared by combining the bark of the plant <italic>Banisteriopsis caapi</italic> vine and the leaves of the <italic>Psychotria viridis</italic> bush<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>. This mixture is boiled for hours and then swallowed since pre-Columbian times by the indigenous tribes of the Amazon Basin<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. In Brazil, ayahuasca is used also for medical therapeutic purposes<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. In mice, the lethal dose of DMT is about 47&#x000a0;mg/kg when given intraperitoneally<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. From rodent studies, the LD<sub>50</sub> of DMT in humans was calculated as 1.6&#x000a0;mg/kg if applied intravenously<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. No human deaths have been reported due to ayahuasca, but when polypharmacy is involved and also 5-MeO-DMT has been taken, one death is reported in the literature<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>.</p><p id="Par28">When DMT alone was administered by injection in humans (0.7&#x02013;1.1&#x000a0;mg/kg body weight) they reported visual hallucinations<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. In humans, a placebo controlled study with intravenous application of DMT led to peak DMT plasma concentrations of about 0.38&#x000a0;&#x000b5;M, an increase in heart rate, and an increase in blood pressure<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. In our study, DMT hardly increased the beating rate in 5-HT<sub>4</sub>-TG mouse right atrial preparations, and the inotropic effects in human atria only began at 10&#x000a0;&#x000b5;M DMT. This discrepancy could simply be due to the difference between the in vivo application of Strassmann et al. and our in vitro application. Consequently, it can be assumed that heart rate and blood pressure are more sensitively affected by a combination of neuronal, vascular and cardiac effects of DMT after intravenous administration. In our experiments, only the direct effects on cardiac myocytes are responsible for any changes in force of contraction (or beating rate). Similarly, when ayahuasca preparations from the Amazon Basin were taken by human volunteers, heart rate and blood pressure augmented<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. Further it was shown that DMT binds to 5-HT<sub>1A,1B,1D</sub>, and 5-HT<sub>2A,2B,2C,6 and 7</sub> receptors<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>. However, 5-MeO-DMT binds with a high affinity to 5-HT<sub>1A,1B,1D</sub>, and 5-HT<sub>5A,6 and 7</sub> receptors, but with a markedly less affinity to 5-HT<sub>2A,2B, and 2C</sub> receptors compared to DMT<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. Unfortunately, the binding affinities of DMT and 5-MeO-DMT to 5-HT<sub>4</sub> receptors are not known, and the investigation of these parameters was beyond the scope of our study. Therefore, we could only compare the functional effects of DMT, 5-MeO-DMT and 5-HT between 5-HT<sub>4</sub>-TG and WT mice.</p><p id="Par29">The present study demonstrated that DMT and 5-MeO-DMT exerted a concentration-dependent positive inotropic effect, and were less potent than 5-HT. Thus, we present data that 5-MeO-DMT and especially DMT, similar to cisapride, are partial agonists on 5-HT<sub>4</sub> receptors, but also noted that the kinetic seems different because it took more time to reach a plateau than 5-HT in 5-HT<sub>4</sub>-TG.</p><p id="Par30">Moreover, we could show that DMT and in particular 5-MeO-DMT can raise the phosphorylation state of phospholamban. This increased phosphorylation state of phospholamban may mediate the contractile effect of 5-MeO-DMT. Any augmented phosphorylation of phospholamban will lead to less inhibition of the Ca<sup>2+</sup> pump (SERCA): SERCA would be pumping faster. This would be expected to lead to a more rapid relaxation of the left atrial preparations from 5-HT<sub>4</sub>-TG mice but not WT mice. Serotonin elevated the phosphorylation state of phospholamban in cardiac preparations from of 5HT<sub>4</sub>-TG<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Likewise, serotonin augmented the phosphorylation state of phospholamban in isolated atrial samples from patients<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>.</p><p id="Par31">It should be noted, however, that there are some limitations of the study: For example, it is debatable whether the results obtained in mouse atria can be extrapolated to humans. The receptor density can be assumed to be different between 5-HT<sub>4</sub>-TG mice and humans and, furthermore, it is not clear if the cellular localization or signal transduction of the transgenic receptor is exactly the same as in human cardiomyocytes. However, this transgenic model has been successfully used several times to analyze cardiac effects of 5-HT and drugs or approved medications acting via 5-HT<sub>4</sub> receptors in comparison to human atria (bufotenin<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>; psilocybin<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>; prucalopride and cisapride<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>). Another limitation is that we were not able examine the EC<sub>50</sub> values of DMT and 5-MeO-DMT neither in our mouse model nor in human preparations. This would have been an opportunity to compare the effects of different drugs on the cardiac 5-HT<sub>4</sub> receptor, but now we can only estimate this. On the other hand, this could mean that at concentrations that induce effects in the central nervous system, cardiac side effects may be unlikely.</p><p id="Par32">In summary, our findings indicate that the hallucinogenic drugs DMT and 5-MeO-DMT can have cardiac side effects via human 5-HT<sub>4</sub> receptors at least under certain circumstances, such as an overdose of DMT or 5-MeO-DMT. This knowledge might become important once DMT and 5-MeO-DMT are described to treat depression.</p></sec><sec id="Sec13" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2025_91400_MOESM1_ESM.pdf"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>
The work contains parts of the medical thesis of Tobias Dietrich. The technical assistance of S. Reber, A. Schmidt, S. Leupold, V. Illgen and P. Willmy is gratefully acknowledged.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>
JN and UG conceived and designed the research. TD and KA conducted experiments. TD, KA and UG analyzed data. BH supplied material and clinical data. JN wrote the first draft. JN and UG wrote and revised the manuscript. All authors read and approved the manuscript. The authors declare that all data were generated in-house and that no paper mill was used.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL.</p><p>Supported by the Deutsche Forschungsgemeinschaft (Grant Number 510383218).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data of this study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par33">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Consent to participate</title><p id="Par330">Informed consent was obtained from all patients included in the study.</p></notes><notes id="FPar3"><title>Consent to publish</title><p id="Par332">All authors declare that they have seen and approved the submitted version of this manuscript.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Ara&#x000fa;jo</surname><given-names>AM</given-names></name><name><surname>Carvalho</surname><given-names>F</given-names></name><name><surname>Bastos</surname><given-names>ML</given-names></name><name><surname>Guedes de Pinho</surname><given-names>P</given-names></name><name><surname>Carvalho</surname><given-names>M</given-names></name></person-group><article-title>The hallucinogenic world of tryptamines: An updated review</article-title><source>Arch. Toxicol.</source><year>2015</year><volume>89</volume><fpage>1151</fpage><lpage>1173</lpage><pub-id pub-id-type="doi">10.1007/s00204-015-1513-x</pub-id><pub-id pub-id-type="pmid">25877327</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Ara&#x000fa;jo, A. M., Carvalho, F., Bastos, M. L., Guedes de Pinho, P. &#x00026; Carvalho, M. The hallucinogenic world of tryptamines: An updated review. <italic>Arch. Toxicol.</italic><bold>89</bold>, 1151&#x02013;1173 (2015).<pub-id pub-id-type="pmid">25877327</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Ott</surname><given-names>J</given-names></name></person-group><article-title>Pharmep&#x000e9;na-psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine</article-title><source>J. Psychoact. Drugs</source><year>2001</year><volume>33</volume><fpage>403</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1080/02791072.2001.10399925</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Ott, J. Pharmep&#x000e9;na-psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine. <italic>J. Psychoact. Drugs</italic><bold>33</bold>, 403&#x02013;407 (2001).</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>H-W</given-names></name><name><surname>Jiang</surname><given-names>X-L</given-names></name><name><surname>Winter</surname><given-names>JC</given-names></name><name><surname>Yu</surname><given-names>A-M</given-names></name></person-group><article-title>Psychedelic 5-methoxy-N,N-dimethyltryptamine: Metabolism, pharmacokinetics, drug interactions, and pharmacological actions</article-title><source>Curr. Drug Metab.</source><year>2010</year><volume>11</volume><fpage>659</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.2174/138920010794233495</pub-id><pub-id pub-id-type="pmid">20942780</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Shen, H.-W., Jiang, X.-L., Winter, J. C. &#x00026; Yu, A.-M. Psychedelic 5-methoxy-N,N-dimethyltryptamine: Metabolism, pharmacokinetics, drug interactions, and pharmacological actions. <italic>Curr. Drug Metab.</italic><bold>11</bold>, 659&#x02013;666 (2010).<pub-id pub-id-type="pmid">20942780</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Brush</surname><given-names>DE</given-names></name><name><surname>Bird</surname><given-names>SB</given-names></name><name><surname>Boyer</surname><given-names>EW</given-names></name></person-group><article-title>Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances</article-title><source>J. Toxicol. Clin. Toxicol.</source><year>2004</year><volume>42</volume><fpage>191</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1081/CLT-120030949</pub-id><pub-id pub-id-type="pmid">15214625</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Brush, D. E., Bird, S. B. &#x00026; Boyer, E. W. Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances. <italic>J. Toxicol. Clin. Toxicol.</italic><bold>42</bold>, 191&#x02013;195 (2004).<pub-id pub-id-type="pmid">15214625</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Titeler</surname><given-names>M</given-names></name><name><surname>Lyon</surname><given-names>RA</given-names></name><name><surname>Glennon</surname><given-names>RA</given-names></name></person-group><article-title>Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens</article-title><source>Psychopharmacology</source><year>1988</year><volume>94</volume><fpage>213</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1007/BF00176847</pub-id><pub-id pub-id-type="pmid">3127847</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Titeler, M., Lyon, R. A. &#x00026; Glennon, R. A. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. <italic>Psychopharmacology</italic><bold>94</bold>, 213&#x02013;216 (1988).<pub-id pub-id-type="pmid">3127847</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Fozard</surname><given-names>JR</given-names></name><name><surname>Ali</surname><given-names>AT</given-names></name></person-group><article-title>Receptors for 5-hydroxytryptamine on the sympathetic nerves of the rabbit heart</article-title><source>Naunyn-Schmiedeberg&#x02019;s Arch. Pharmacol.</source><year>1978</year><volume>301</volume><fpage>223</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1007/BF00507041</pub-id><pub-id pub-id-type="pmid">634380</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Fozard, J. R. &#x00026; Ali, A. T. Receptors for 5-hydroxytryptamine on the sympathetic nerves of the rabbit heart. <italic>Naunyn-Schmiedeberg&#x02019;s Arch. Pharmacol.</italic><bold>301</bold>, 223&#x02013;235 (1978).<pub-id pub-id-type="pmid">634380</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Trendelenburg</surname><given-names>U</given-names></name></person-group><article-title>The action of histamine and 5-hydroxytryptamine on isolated mammalian atria</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1960</year><volume>130</volume><fpage>450</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/S0022-3565(25)25923-7</pub-id><pub-id pub-id-type="pmid">13777992</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Trendelenburg, U. The action of histamine and 5-hydroxytryptamine on isolated mammalian atria. <italic>J. Pharmacol. Exp. Ther.</italic><bold>130</bold>, 450&#x02013;460 (1960).<pub-id pub-id-type="pmid">13777992</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Dabire</surname><given-names>H</given-names></name><name><surname>Cherqui</surname><given-names>C</given-names></name><name><surname>Fournier</surname><given-names>B</given-names></name><name><surname>Schmitt</surname><given-names>H</given-names></name></person-group><article-title>Comparison of effects of some 5-HT1 agonists on blood pressure and heart rate of normotensive anaesthetized rats</article-title><source>Eur. J. Pharmacol.</source><year>1987</year><volume>140</volume><fpage>259</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(87)90282-2</pub-id><pub-id pub-id-type="pmid">2958302</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Dabire, H., Cherqui, C., Fournier, B. &#x00026; Schmitt, H. Comparison of effects of some 5-HT1 agonists on blood pressure and heart rate of normotensive anaesthetized rats. <italic>Eur. J. Pharmacol.</italic><bold>140</bold>, 259&#x02013;266 (1987).<pub-id pub-id-type="pmid">2958302</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000e4;er</surname><given-names>S</given-names></name><etal/></person-group><article-title>Receptor mechanisms involved in the 5-HT-induced inotropic action in the rat isolated atrium</article-title><source>Br. J. Pharmacol.</source><year>1998</year><volume>123</volume><fpage>1182</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0701702</pub-id><pub-id pub-id-type="pmid">9559903</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">L&#x000e4;er, S. et al. Receptor mechanisms involved in the 5-HT-induced inotropic action in the rat isolated atrium. <italic>Br. J. Pharmacol.</italic><bold>123</bold>, 1182&#x02013;1188 (1998).<pub-id pub-id-type="pmid">9559903</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Dietrich, T., Gergs, U., Hofmann, B., H&#x000f6;hm, C. &#x00026; Neumann, J. In <italic>8th German Pharm-Tox Summit 2023: Abstracts of the 89. Jahrestagung der Deutschen Gesellschaft f&#x000fc;r Experimentelle und Klinische Pharmakologie und Toxikologie (DGPT) in Zusammenarbeit mit der AGAH</italic> (2023), 44.</mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Jacob, H. <italic>et al.</italic> Positive inotropic effects of hallucinogenic drugs in isolated human atrial preparations. In <italic>20th Meeting of International Society for Serotonin Research, Canc&#x000fa;n, Mexico</italic> (2023).</mixed-citation></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Gergs</surname><given-names>U</given-names></name><etal/></person-group><article-title>Cardiac overexpression of the human 5-HT4 receptor in mice</article-title><source>Am. J. Physiol. Heart Circ. Physiol.</source><year>2010</year><volume>299</volume><fpage>H788</fpage><lpage>H798</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00691.2009</pub-id><pub-id pub-id-type="pmid">20639221</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Gergs, U. et al. Cardiac overexpression of the human 5-HT4 receptor in mice. <italic>Am. J. Physiol. Heart Circ. Physiol.</italic><bold>299</bold>, H788&#x02013;H798 (2010).<pub-id pub-id-type="pmid">20639221</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Kilkenny</surname><given-names>C</given-names></name><name><surname>Browne</surname><given-names>WJ</given-names></name><name><surname>Cuthill</surname><given-names>IC</given-names></name><name><surname>Emerson</surname><given-names>M</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research</article-title><source>PLoS Biol.</source><year>2010</year><volume>8</volume><fpage>e1000412</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.1000412</pub-id><pub-id pub-id-type="pmid">20613859</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. &#x00026; Altman, D. G. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. <italic>PLoS Biol.</italic><bold>8</bold>, e1000412 (2010).<pub-id pub-id-type="pmid">20613859</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Laferriere</surname><given-names>CA</given-names></name><name><surname>Pang</surname><given-names>DS</given-names></name></person-group><article-title>Review of intraperitoneal injection of sodium pentobarbital as a method of euthanasia in laboratory rodents</article-title><source>J. Am. Assoc. Lab. Anim. Sci. JAALAS</source><year>2020</year><volume>59</volume><fpage>254</fpage><lpage>263</lpage></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Laferriere, C. A. &#x00026; Pang, D. S. Review of intraperitoneal injection of sodium pentobarbital as a method of euthanasia in laboratory rodents. <italic>J. Am. Assoc. Lab. Anim. Sci. JAALAS</italic><bold>59</bold>, 254&#x02013;263 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Gergs</surname><given-names>U</given-names></name><etal/></person-group><article-title>Human 5-HT<sub>4</sub> receptor stimulation in atria of transgenic mice</article-title><source>Naunyn-Schmiedeberg&#x02019;s Arch. Pharmacol.</source><year>2013</year><volume>386</volume><fpage>357</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1007/s00210-013-0831-x</pub-id><pub-id pub-id-type="pmid">23307014</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Gergs, U. et al. Human 5-HT<sub>4</sub> receptor stimulation in atria of transgenic mice. <italic>Naunyn-Schmiedeberg&#x02019;s Arch. Pharmacol.</italic><bold>386</bold>, 357&#x02013;367 (2013).<pub-id pub-id-type="pmid">23307014</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>J</given-names></name><name><surname>Boknik</surname><given-names>P</given-names></name><name><surname>Matherne</surname><given-names>GP</given-names></name><name><surname>Lankford</surname><given-names>A</given-names></name><name><surname>Schmitz</surname><given-names>W</given-names></name></person-group><article-title>Pertussis toxin sensitive and insensitive effects of adenosine and carbachol in murine atria overexpressing A(1)-adenosine receptors</article-title><source>Br. J. Pharmacol.</source><year>2003</year><volume>138</volume><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0705012</pub-id><pub-id pub-id-type="pmid">12522092</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Neumann, J., Boknik, P., Matherne, G. P., Lankford, A. &#x00026; Schmitz, W. Pertussis toxin sensitive and insensitive effects of adenosine and carbachol in murine atria overexpressing A(1)-adenosine receptors. <italic>Br. J. Pharmacol.</italic><bold>138</bold>, 209&#x02013;217 (2003).<pub-id pub-id-type="pmid">12522092</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>J</given-names></name><etal/></person-group><article-title>Targeted overexpression of phospholamban to mouse atrium depresses Ca<sup>2+</sup> transport and contractility</article-title><source>J. Mol. Cell. Cardiol.</source><year>1998</year><volume>30</volume><fpage>1991</fpage><lpage>2002</lpage><pub-id pub-id-type="doi">10.1006/jmcc.1998.0760</pub-id><pub-id pub-id-type="pmid">9799653</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Neumann, J. et al. Targeted overexpression of phospholamban to mouse atrium depresses Ca<sup>2+</sup> transport and contractility. <italic>J. Mol. Cell. Cardiol.</italic><bold>30</bold>, 1991&#x02013;2002 (1998).<pub-id pub-id-type="pmid">9799653</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchhefer</surname><given-names>U</given-names></name><etal/></person-group><article-title>Age-dependent biochemical and contractile properties in atrium of transgenic mice overexpressing junctin</article-title><source>Am. J. Physiol. Heart Circ. Physiol.</source><year>2004</year><volume>287</volume><fpage>H2216</fpage><lpage>H2225</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00137.2004</pub-id><pub-id pub-id-type="pmid">15205169</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Kirchhefer, U. et al. Age-dependent biochemical and contractile properties in atrium of transgenic mice overexpressing junctin. <italic>Am. J. Physiol. Heart Circ. Physiol.</italic><bold>287</bold>, H2216&#x02013;H2225 (2004).<pub-id pub-id-type="pmid">15205169</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Gergs</surname><given-names>U</given-names></name><etal/></person-group><article-title>Phosphorylation of phospholamban and troponin I through 5-HT4 receptors in the isolated human atrium</article-title><source>Naunyn-Schmiedeberg&#x02019;s Arch. Pharmacol.</source><year>2009</year><volume>379</volume><fpage>349</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1007/s00210-008-0371-y</pub-id><pub-id pub-id-type="pmid">19002436</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Gergs, U. et al. Phosphorylation of phospholamban and troponin I through 5-HT4 receptors in the isolated human atrium. <italic>Naunyn-Schmiedeberg&#x02019;s Arch. Pharmacol.</italic><bold>379</bold>, 349&#x02013;359 (2009).<pub-id pub-id-type="pmid">19002436</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Gergs</surname><given-names>U</given-names></name><etal/></person-group><article-title>Pharmacological and physiological assessment of serotonin formation and degradation in isolated preparations from mouse and human hearts</article-title><source>Am. J. Physiol. Heart Circ. Physiol.</source><year>2017</year><volume>313</volume><fpage>H1087</fpage><lpage>H1097</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00350.2017</pub-id><pub-id pub-id-type="pmid">28916638</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Gergs, U. et al. Pharmacological and physiological assessment of serotonin formation and degradation in isolated preparations from mouse and human hearts. <italic>Am. J. Physiol. Heart Circ. Physiol.</italic><bold>313</bold>, H1087&#x02013;H1097 (2017).<pub-id pub-id-type="pmid">28916638</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Gergs</surname><given-names>U</given-names></name><etal/></person-group><article-title>Mechanism underlying the contractile activity of UTP in the mammalian heart</article-title><source>Eur. J. Pharmacol.</source><year>2018</year><volume>830</volume><fpage>47</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2018.04.013</pub-id><pub-id pub-id-type="pmid">29673908</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Gergs, U. et al. Mechanism underlying the contractile activity of UTP in the mammalian heart. <italic>Eur. J. Pharmacol.</italic><bold>830</bold>, 47&#x02013;58 (2018).<pub-id pub-id-type="pmid">29673908</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Boknik</surname><given-names>P</given-names></name><etal/></person-group><article-title>Evidence for arrhythmogenic effects of A2A-adenosine receptors</article-title><source>Front. Pharmacol.</source><year>2019</year><volume>10</volume><fpage>1051</fpage><pub-id pub-id-type="doi">10.3389/fphar.2019.01051</pub-id><pub-id pub-id-type="pmid">31619997</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Boknik, P. et al. Evidence for arrhythmogenic effects of A2A-adenosine receptors. <italic>Front. Pharmacol.</italic><bold>10</bold>, 1051 (2019).<pub-id pub-id-type="pmid">31619997</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Gergs</surname><given-names>U</given-names></name><etal/></person-group><article-title>Initial characterization of transgenic mice overexpressing human histamine H2 receptors</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2019</year><volume>369</volume><fpage>129</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1124/jpet.118.255711</pub-id><pub-id pub-id-type="pmid">30728249</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Gergs, U. et al. Initial characterization of transgenic mice overexpressing human histamine H2 receptors. <italic>J. Pharmacol. Exp. Ther.</italic><bold>369</bold>, 129&#x02013;141 (2019).<pub-id pub-id-type="pmid">30728249</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Gergs</surname><given-names>U</given-names></name><etal/></person-group><article-title>Overexpression of protein phosphatase 5 in the mouse heart: Reduced contractility but increased stress tolerance&#x02014;Two sides of the same coin?</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><fpage>e0221289</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0221289</pub-id><pub-id pub-id-type="pmid">31425567</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Gergs, U. et al. Overexpression of protein phosphatase 5 in the mouse heart: Reduced contractility but increased stress tolerance&#x02014;Two sides of the same coin?. <italic>PLoS ONE</italic><bold>14</bold>, e0221289 (2019).<pub-id pub-id-type="pmid">31425567</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Boknik</surname><given-names>P</given-names></name><etal/></person-group><article-title>Phenotyping of mice with heart specific overexpression of A2A-adenosine receptors: Evidence for cardioprotective effects of A2A-adenosine receptors</article-title><source>Front. Pharmacol.</source><year>2018</year><volume>9</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.00013</pub-id><pub-id pub-id-type="pmid">29403384</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Boknik, P. et al. Phenotyping of mice with heart specific overexpression of A2A-adenosine receptors: Evidence for cardioprotective effects of A2A-adenosine receptors. <italic>Front. Pharmacol.</italic><bold>9</bold>, 13 (2018).<pub-id pub-id-type="pmid">29403384</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Gergs</surname><given-names>U</given-names></name><name><surname>Fritsche</surname><given-names>J</given-names></name><name><surname>Fabian</surname><given-names>S</given-names></name><name><surname>Christ</surname><given-names>J</given-names></name><name><surname>Neumann</surname><given-names>J</given-names></name></person-group><article-title>Desensitization of the human 5-HT4 receptor in isolated atria of transgenic mice</article-title><source>Naunyn-Schmiedeberg&#x02019;s Arch. Pharmacol.</source><year>2017</year><volume>390</volume><fpage>987</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1007/s00210-017-1403-2</pub-id><pub-id pub-id-type="pmid">28689254</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Gergs, U., Fritsche, J., Fabian, S., Christ, J. &#x00026; Neumann, J. Desensitization of the human 5-HT4 receptor in isolated atria of transgenic mice. <italic>Naunyn-Schmiedeberg&#x02019;s Arch. Pharmacol.</italic><bold>390</bold>, 987&#x02013;996 (2017).<pub-id pub-id-type="pmid">28689254</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Winstock</surname><given-names>AR</given-names></name><name><surname>Kaar</surname><given-names>S</given-names></name><name><surname>Borschmann</surname><given-names>R</given-names></name></person-group><article-title>Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample</article-title><source>J. Psychopharmacol. (Oxf. Engl.)</source><year>2014</year><volume>28</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1177/0269881113513852</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Winstock, A. R., Kaar, S. &#x00026; Borschmann, R. Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample. <italic>J. Psychopharmacol. (Oxf. Engl.)</italic><bold>28</bold>, 49&#x02013;54 (2014).</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>DJ</given-names></name><name><surname>Towers</surname><given-names>GH</given-names></name><name><surname>Abbott</surname><given-names>F</given-names></name></person-group><article-title>Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and beta-carboline constituents of ayahuasca</article-title><source>J. Ethnopharmacol.</source><year>1984</year><volume>10</volume><fpage>195</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/0378-8741(84)90003-5</pub-id><pub-id pub-id-type="pmid">6587171</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">McKenna, D. J., Towers, G. H. &#x00026; Abbott, F. Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and beta-carboline constituents of ayahuasca. <italic>J. Ethnopharmacol.</italic><bold>10</bold>, 195&#x02013;223 (1984).<pub-id pub-id-type="pmid">6587171</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Gable</surname><given-names>RS</given-names></name></person-group><article-title>Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids</article-title><source>Addiction (Abingdon, England)</source><year>2007</year><volume>102</volume><fpage>24</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1111/j.1360-0443.2006.01652.x</pub-id><pub-id pub-id-type="pmid">17207120</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Gable, R. S. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. <italic>Addiction (Abingdon, England)</italic><bold>102</bold>, 24&#x02013;34 (2007).<pub-id pub-id-type="pmid">17207120</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Ott</surname><given-names>J</given-names></name></person-group><article-title>Pharmahuasca: Human pharmacology of oral DMT plus harmine</article-title><source>J. Psychoact. Drugs</source><year>1999</year><volume>31</volume><fpage>171</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1080/02791072.1999.10471741</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Ott, J. Pharmahuasca: Human pharmacology of oral DMT plus harmine. <italic>J. Psychoact. Drugs</italic><bold>31</bold>, 171&#x02013;177 (1999).</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Brito-da-Costa</surname><given-names>AM</given-names></name><name><surname>Dias-da-Silva</surname><given-names>D</given-names></name><name><surname>Gomes</surname><given-names>NGM</given-names></name><name><surname>Dinis-Oliveira</surname><given-names>RJ</given-names></name><name><surname>Madureira-Carvalho</surname><given-names>&#x000c1;</given-names></name></person-group><article-title>Toxicokinetics and toxicodynamics of ayahuasca alkaloids N,N-dimethyltryptamine (DMT), harmine, harmaline and tetrahydroharmine: Clinical and forensic impact</article-title><source>Pharmaceuticals (Basel, Switzerland)</source><year>2020</year><volume>13</volume><fpage>334</fpage><pub-id pub-id-type="doi">10.3390/ph13110334</pub-id><pub-id pub-id-type="pmid">33114119</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Brito-da-Costa, A. M., Dias-da-Silva, D., Gomes, N. G. M., Dinis-Oliveira, R. J. &#x00026; Madureira-Carvalho, &#x000c1;. Toxicokinetics and toxicodynamics of ayahuasca alkaloids N,N-dimethyltryptamine (DMT), harmine, harmaline and tetrahydroharmine: Clinical and forensic impact. <italic>Pharmaceuticals (Basel, Switzerland)</italic><bold>13</bold>, 334 (2020).<pub-id pub-id-type="pmid">33114119</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Callaway</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Pharmacokinetics of Hoasca alkaloids in healthy humans</article-title><source>J. Ethnopharmacol.</source><year>1999</year><volume>65</volume><fpage>243</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/S0378-8741(98)00168-8</pub-id><pub-id pub-id-type="pmid">10404423</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Callaway, J. C. et al. Pharmacokinetics of Hoasca alkaloids in healthy humans. <italic>J. Ethnopharmacol.</italic><bold>65</bold>, 243&#x02013;256 (1999).<pub-id pub-id-type="pmid">10404423</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Sklerov</surname><given-names>J</given-names></name><name><surname>Levine</surname><given-names>B</given-names></name><name><surname>Moore</surname><given-names>KA</given-names></name><name><surname>King</surname><given-names>T</given-names></name><name><surname>Fowler</surname><given-names>D</given-names></name></person-group><article-title>A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation</article-title><source>J. Anal. Toxicol.</source><year>2005</year><volume>29</volume><fpage>838</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1093/jat/29.8.838</pub-id><pub-id pub-id-type="pmid">16356341</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Sklerov, J., Levine, B., Moore, K. A., King, T. &#x00026; Fowler, D. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. <italic>J. Anal. Toxicol.</italic><bold>29</bold>, 838&#x02013;841 (2005).<pub-id pub-id-type="pmid">16356341</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Szara</surname><given-names>S</given-names></name></person-group><article-title>Dimethyltryptamin: Its metabolism in man; The relation to its psychotic effect to the serotonin metabolism</article-title><source>Experientia</source><year>1956</year><volume>12</volume><fpage>441</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1007/BF02157378</pub-id><pub-id pub-id-type="pmid">13384414</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Szara, S. Dimethyltryptamin: Its metabolism in man; The relation to its psychotic effect to the serotonin metabolism. <italic>Experientia</italic><bold>12</bold>, 441&#x02013;442 (1956).<pub-id pub-id-type="pmid">13384414</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Strassman</surname><given-names>RJ</given-names></name><name><surname>Qualls</surname><given-names>CR</given-names></name></person-group><article-title>Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects</article-title><source>Arch. Gen. Psychiatry</source><year>1994</year><volume>51</volume><fpage>85</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1994.03950020009001</pub-id><pub-id pub-id-type="pmid">8297216</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Strassman, R. J. &#x00026; Qualls, C. R. Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. <italic>Arch. Gen. Psychiatry</italic><bold>51</bold>, 85&#x02013;97 (1994).<pub-id pub-id-type="pmid">8297216</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Deliganis</surname><given-names>AV</given-names></name><name><surname>Pierce</surname><given-names>PA</given-names></name><name><surname>Peroutka</surname><given-names>SJ</given-names></name></person-group><article-title>Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors</article-title><source>Biochem. Pharmacol.</source><year>1991</year><volume>41</volume><fpage>1739</fpage><lpage>1744</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(91)90178-8</pub-id><pub-id pub-id-type="pmid">1828347</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Deliganis, A. V., Pierce, P. A. &#x00026; Peroutka, S. J. Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors. <italic>Biochem. Pharmacol.</italic><bold>41</bold>, 1739&#x02013;1744 (1991).<pub-id pub-id-type="pmid">1828347</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Holze</surname><given-names>F</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name><name><surname>D'Souza</surname><given-names>DC</given-names></name></person-group><article-title>Serotonergic psychedelics: A comparative review of efficacy, safety, pharmacokinetics, and binding profile</article-title><source>Biol. Psychiatry Cogn. Neurosci. Neuroimaging</source><year>2024</year><volume>9</volume><fpage>472</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">38301886</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Holze, F., Singh, N., Liechti, M. E. &#x00026; D&#x02019;Souza, D. C. Serotonergic psychedelics: A comparative review of efficacy, safety, pharmacokinetics, and binding profile. <italic>Biol. Psychiatry Cogn. Neurosci. Neuroimaging</italic><bold>9</bold>, 472&#x02013;489 (2024).<pub-id pub-id-type="pmid">38301886</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cardiovascular effects of bufotenin on human 5-HT4 serotonin receptors in cardiac preparations of transgenic mice and in human atrial preparations</article-title><source>Naunyn-Schmiedeberg&#x02019;s Arch. Pharmacol.</source><year>2023</year><volume>396</volume><fpage>1471</fpage><lpage>1485</lpage><pub-id pub-id-type="doi">10.1007/s00210-023-02414-8</pub-id><pub-id pub-id-type="pmid">36754881</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Neumann, J. et al. Cardiovascular effects of bufotenin on human 5-HT4 serotonin receptors in cardiac preparations of transgenic mice and in human atrial preparations. <italic>Naunyn-Schmiedeberg&#x02019;s Arch. Pharmacol.</italic><bold>396</bold>, 1471&#x02013;1485 (2023).<pub-id pub-id-type="pmid">36754881</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>J</given-names></name><name><surname>Dimov</surname><given-names>K</given-names></name><name><surname>Azatsian</surname><given-names>K</given-names></name><name><surname>Hofmann</surname><given-names>B</given-names></name><name><surname>Gergs</surname><given-names>U</given-names></name></person-group><article-title>Effects of psilocin and psilocybin on human 5-HT4 serotonin receptors in atrial preparations of transgenic mice and humans</article-title><source>Toxicol. Lett.</source><year>2024</year><volume>398</volume><fpage>55</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2024.06.006</pub-id><pub-id pub-id-type="pmid">38876450</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Neumann, J., Dimov, K., Azatsian, K., Hofmann, B. &#x00026; Gergs, U. Effects of psilocin and psilocybin on human 5-HT4 serotonin receptors in atrial preparations of transgenic mice and humans. <italic>Toxicol. Lett.</italic><bold>398</bold>, 55&#x02013;64 (2024).<pub-id pub-id-type="pmid">38876450</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>N</given-names></name><name><surname>Dhein</surname><given-names>S</given-names></name><name><surname>Neumann</surname><given-names>J</given-names></name><name><surname>Gergs</surname><given-names>U</given-names></name></person-group><article-title>Cardiovascular effects of cisapride and prucalopride on human 5-HT4 receptors in transgenic mice</article-title><source>Naunyn-Schmiedeberg&#x02019;s Arch. Pharmacol.</source><year>2018</year><volume>391</volume><fpage>975</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1007/s00210-018-1519-z</pub-id><pub-id pub-id-type="pmid">29947908</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Keller, N., Dhein, S., Neumann, J. &#x00026; Gergs, U. Cardiovascular effects of cisapride and prucalopride on human 5-HT4 receptors in transgenic mice. <italic>Naunyn-Schmiedeberg&#x02019;s Arch. Pharmacol.</italic><bold>391</bold>, 975&#x02013;985 (2018).<pub-id pub-id-type="pmid">29947908</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>